Recurrent Fallopian Tube Carcinoma

Oncology
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
GuadecitabinePhase 2
M&
Merck & Co.RAHWAY, NJ
1 program
1
PembrolizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03732950Active Not Recruiting5Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Pembrolizumab

Clinical Trials (1)

Total enrollment: 5 patients across 1 trials

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Start: Mar 2019Est. completion: Mar 20255 patients
Phase 2Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space